Cogent Biosciences Inc [COGT] stock is trading at $6.99, up 7.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The COGT shares have gain 3.56% over the last week, with a monthly amount glided 6.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cogent Biosciences Inc [NASDAQ: COGT] stock has seen the most recent analyst activity on February 26, 2024, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $8 from $14. Previously, Citigroup started tracking the stock with Buy rating on February 08, 2024, and set its price target to $11. On December 11, 2023, downgrade downgraded it’s rating to Neutral but maintained its price target of $5 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $18 on December 08, 2023. Robert W. Baird initiated its recommendation with a Outperform and recommended $20 as its price target on April 28, 2023. In a note dated December 14, 2022, Needham initiated an Buy rating and provided a target price of $24 on this stock.
Cogent Biosciences Inc [COGT] stock has fluctuated between $3.67 and $13.50 over the past year. Currently, Wall Street analysts expect the stock to reach $20.25 within the next 12 months. Cogent Biosciences Inc [NASDAQ: COGT] shares were valued at $6.99 at the most recent close of the market. An investor can expect a potential return of 189.7% based on the average COGT price forecast.
Analyzing the COGT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.66 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.45 points at the first support level, and at 5.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.29, and for the 2nd resistance point, it is at 7.60.
Ratios To Look Out For
For context, Cogent Biosciences Inc’s Current Ratio is 7.09. As well, the Quick Ratio is 7.09, while the Cash Ratio is 1.39.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, 10% Owner, that happened on Jun 09 ’23 when 0.8 million shares were purchased.
